Clostridioides difficile infection (CDI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Clostridioides difficile infection (CDI)

Clostridioides difficile infection (CDI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Spinocerebellar ataxia (SCA) is a term referring to a group of hereditary ataxias that are characterized by degenerative changes in the part of the brain related to the movement control (cerebellum), and sometimes in the spinal cord.

Clostridioides difficile infection (CDI) has become a major nosocomial disease, associated with serious morbidity and potential mortality. Symptoms include diarrhea, fever, abdominal pain, and leukocytosis. A severe infection might lead to pseudomembranous colitis and toxic megacolon, which, in extreme cases, can be lethal. The risk factors for CDI include age over 65, hospitalization in an intensive care unit (ICU), background of inflammatory bowel diseases, chemotherapy, and antibiotic therapy.

Cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are relatively effective, however the risk of recurrence is evident. High rates of CDI recurrence, increasing mortality, and the hospitalization rate increases the financial burden.

CDI can be primarily classified into Non-Fulminant Disease & Fulminant Disease, Initial Episode, First Recurrence, Second Recurrence , Type of settings; Chronic and recurrent CDI, Severity; Mild, Moderate, Severe cases.

The overall age and sex adjusted CDI incidence in the USA was ranges between 143.5 to 157.8 cases per 100,000 populations. There were 345K to 356K CDI-related hospitalizations being reported in 2019. This accounted for 0.9% to 1.21% of all hospitalizations in the year. Out of these hospitalizations, 29.3% had CDI as a principal diagnosis and 70.7% of the hospitalizations had CDI as a secondary diagnosis. Epidemiology section of the study provides a Comprehensive insight on patient segmentation based on age, sex, Type of settings; Chronic and recurrent CDI, Severity (Mild, Moderate, Severe), Risk factors (Drug induced, CKD, diabetes mellitus, lymphoma or leukemia, or Solid tumors, IBD, CHF, COPD, Ulcer, GERD, and others) in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

Competitive landscape of Clostridioides difficile infection (CDI) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Clostridioides difficile infection (CDI) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Clostridioides difficile infection (CDI) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Clostridioides difficile infection (CDI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

S. No        Asset        Company        Stage

1        CRS3123        Crestone, Inc        Phase 2

2        SER-109        Seres Therapeutics, Inc.        Phase 3

3        SER-262        Pharm-Olam International        Phase 1

4        ridinilazole        Summit Therapeutics        Phase 3

5        Ibezapolstat        Acurx Pharmaceuticals LLC        Phase 2

6        RBX2660        Rebiotix Inc.        Phase 3

7        Placebo        Artugen Therapeutics USA, Inc.        Phase 1

8        SOC        Merck Sharp & Dohme Corp.        Phase 3

9        IM-01        ImmuniMed Inc.        Phase 2

10        LFF571        Novartis Pharmaceuticals        Phase 2

11        RBX7455        Mayo Clinic        Phase 1

12        CP101        Medpace, Inc.        Phase 2

13        Cadazolid        Actelion        Phase 3

14        VE303        Vedanta Biosciences, Inc.        Phase 2

15        CB-183,315        Cubist Pharmaceuticals LLC        Phase 3

16        Clostridium difficile vaccine        Pfizer        Phase 3

17        MGB-BP-3        MGB Biopharma Limited        Phase 2

18        DNV3837        Deinove        Phase 2

19        Clostridium difficile toxoids A and B (Low-dose with adjuvant)        Sanofi        Phase 2

20        Fidaxomicin oral suspension        Astellas Pharma Europe B.V.        Phase 3

21        GS-CDA1/MDX-1388        MassBiologics        Phase 2

22        Placebo        GlaxoSmithKline        Phase 1

23        SYN-004        Synthetic Biologics Inc.        Phase 2

24        GS-CDA1/MDX-1388        Medarex        Phase 2

25        Rifaximin (Xifaxan)        Bausch Health Americas, Inc.        Phase 3

26        VLA84        Valneva Austria GmbH        Phase 2

27        OPT-80        Astellas Pharma Inc        Phase 3

28        fidaxomicin        Optimer Pharmaceuticals LLC        Phase 3

29        MGB-BP-3        Syneos Health        Phase 2